Table 1.
Parameter and value Table [11].
Fig 1.
Changes in the proportion of untreated subgroups.
(A) Initial low cancer cell proportion. (B) Initial high cancer cell proportion. (C) Initial medium cancer cell proportion.
Fig 2.
Maximum tolerated dose (MTD) treatment scheme.
(A) Temporal evolution of various cell subpopulation proportions during 25 days of continuous treatment at the maximum tolerated dose and following cessation of treatment. (B) Temporal evolution of the overall proportion of cancer cells.
Fig 3.
Low-dose continuous treatment (drug dose m=0.352).
(A) Temporal evolution of the proportions of various cell subpopulations. (B) Temporal evolution of the overall proportion of cancer cells.
Fig 4.
Metronomic therapy (drug dose m=0.5, treatment interval of 12.5 days).
(A) Temporal evolution of the proportions of various cell subpopulations. (B) Temporal evolution of the overall proportion of cancer cells.
Fig 5.
(A) Drug dosage. (B) Drug concentration changes.
Fig 6.
(A) Temporal evolution of the proportions of various cell subpopulations, Pale yellow and white backgrounds respectively indicate the treatment phase and the treatment interval phase (This will not be repeated further in the text.). (B) Temporal evolution of the overall proportion of cancer cells.
Fig 7.
Comparison of treatment plans.
(A) MTD treatment scheme:Temporal evolution of the proportions of various cell subpopulations. (B) MTD treatment scheme: Temporal evolution of the overall proportion of cancer cells. (C) Metronomic therapy scheme: Temporal evolution of the proportions of various cell subpopulations. (D) Metronomic therapy scheme: Temporal evolution of the overall proportion of cancer cells. (E) Optimal adaptive therapy scheme: Temporal evolution of the proportions of various cell subpopulations. (F) Optimal adaptive therapy scheme: Temporal evolution of the overall proportion of cancer cells.
Fig 8.
Below are the fitness functions for healthy cells, drug-sensitive cells, and drug-resistant cells.
(A) Fitness functions under the MTD treatment scheme. (B) Fitness functions under the metronomic therapy scheme. (C) Fitness functions under the optimal adaptive therapy scheme.
Fig 9.
Personalized treatment for low tumor burden cases.
(A)Temporal evolution of the proportions of various cell subpopulations. (B) Temporal evolution of the overall proportion of cancer cells. (C) Drug dosage. (D) Changes in drug concentration.
Fig 10.
Personalized treatment for high tumor burden cases.
(A)Temporal evolution of the proportions of various cell subpopulations. (B) Temporal evolution of the overall proportion of cancer cells. (C) Drug dosage. (D) Changes in drug concentration.